Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1994 Oct;68(10):6578–6588. doi: 10.1128/jvi.68.10.6578-6588.1994

Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.

K Schlienger 1, D C Montefiori 1, M Mancini 1, Y Rivière 1, P Tiollais 1, M L Michel 1
PMCID: PMC237078  PMID: 7521918

Abstract

The potential of the simian immunodeficiency virus (SIV) variable 2 (V2) domain as an effective region to boost SIV-neutralizing antibodies and to protect against live SIV challenge was tested in rhesus macaques. In this study, two rhesus macaques were primed with vaccinia virus recombinants expressing the surface glycoprotein gp140 of SIVmac and were given booster injections with the SIVmac V2 domain presented by a highly immunogenic carrier, the hepatitis B surface antigen (HBsAg). The two vaccinated macaques exhibited SIV-neutralizing antibodies after primer injections that were enhanced by the V2/HBsAg injections. Part of these SIV-neutralizing antibodies were directed specifically to the V2 region, as shown by neutralization-blocking experiments. However, despite having consistent SIV-neutralizing antibody titers, animals were not protected against homologous challenge with BK28, the molecular clone of SIVmac251. No SIV envelope-specific cellular cytotoxic response was detected throughout the immunization protocol, suggesting that neutralizing antibodies directed to SIV envelope gp140 and especially to the V2 domain were unable on their own to protect against SIV challenge. Furthermore, the vaccinees seemed to have higher viral loads than control animals after challenge, raising the question of whether neutralizing antibodies induced by vaccination and directed to the SIV envelope selected viral escape mutants, as shown previously in SIV-infected macaques. This mechanism is certainly worthy of intensive investigation and raises some concern for SIV envelope-targeted immunization.

Full text

PDF
6578

Images in this article

6581Image
on p.6581

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alter H. J., Eichberg J. W., Masur H., Saxinger W. C., Gallo R., Macher A. M., Lane H. C., Fauci A. S. Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science. 1984 Nov 2;226(4674):549–552. doi: 10.1126/science.6093251. [DOI] [PubMed] [Google Scholar]
  2. Andeweg A. C., Leeflang P., Osterhaus A. D., Bosch M. L. Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. J Virol. 1993 Jun;67(6):3232–3239. doi: 10.1128/jvi.67.6.3232-3239.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arthur L. O., Bess J. W., Jr, Sowder R. C., 2nd, Benveniste R. E., Mann D. L., Chermann J. C., Henderson L. E. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science. 1992 Dec 18;258(5090):1935–1938. doi: 10.1126/science.1470916. [DOI] [PubMed] [Google Scholar]
  4. Benichou S., Legrand R., Nakagawa N., Faure T., Traincard F., Vogt G., Dormont D., Tiollais P., Kieny M. P., Madaule P. Identification of a neutralizing domain in the external envelope glycoprotein of simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1992 Jun;8(6):1165–1170. doi: 10.1089/aid.1992.8.1165. [DOI] [PubMed] [Google Scholar]
  5. Benichou S., Venet A., Beyer C., Tiollais P., Madaule P. Characterization of B-cell epitopes in the envelope glycoproteins of simian immunodeficiency virus. Virology. 1993 Jun;194(2):870–874. doi: 10.1006/viro.1993.1333. [DOI] [PubMed] [Google Scholar]
  6. Berman P. W., Gregory T. J., Riddle L., Nakamura G. R., Champe M. A., Porter J. P., Wurm F. M., Hershberg R. D., Cobb E. K., Eichberg J. W. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 1990 Jun 14;345(6276):622–625. doi: 10.1038/345622a0. [DOI] [PubMed] [Google Scholar]
  7. Burns D. P., Collignon C., Desrosiers R. C. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J Virol. 1993 Jul;67(7):4104–4113. doi: 10.1128/jvi.67.7.4104-4113.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Carlson J. R., McGraw T. P., Keddie E., Yee J. L., Rosenthal A., Langlois A. J., Dickover R., Donovan R., Luciw P. A., Jennings M. B. Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Res Hum Retroviruses. 1990 Nov;6(11):1239–1246. doi: 10.1089/aid.1990.6.1239. [DOI] [PubMed] [Google Scholar]
  9. Cranage M. P., Ashworth L. A., Greenaway P. J., Murphey-Corb M., Desrosiers R. C. AIDS vaccine developments. Nature. 1992 Feb 20;355(6362):685–686. doi: 10.1038/355685a0. [DOI] [PubMed] [Google Scholar]
  10. D'Souza M. P., Kent K. A., Thiriart C., Collignon C., Milman G. International collaboration comparing neutralization and binding assays for monoclonal antibodies to simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1993 May;9(5):415–422. doi: 10.1089/aid.1993.9.415. [DOI] [PubMed] [Google Scholar]
  11. Daniel M. D., Kirchhoff F., Czajak S. C., Sehgal P. K., Desrosiers R. C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992 Dec 18;258(5090):1938–1941. doi: 10.1126/science.1470917. [DOI] [PubMed] [Google Scholar]
  12. Daniel M. D., Letvin N. L., King N. W., Kannagi M., Sehgal P. K., Hunt R. D., Kanki P. J., Essex M., Desrosiers R. C. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science. 1985 Jun 7;228(4704):1201–1204. doi: 10.1126/science.3159089. [DOI] [PubMed] [Google Scholar]
  13. Desrosiers R. C., Wyand M. S., Kodama T., Ringler D. J., Arthur L. O., Sehgal P. K., Letvin N. L., King N. W., Daniel M. D. Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6353–6357. doi: 10.1073/pnas.86.16.6353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Emini E. A., Schleif W. A., Nunberg J. H., Conley A. J., Eda Y., Tokiyoshi S., Putney S. D., Matsushita S., Cobb K. E., Jett C. M. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature. 1992 Feb 20;355(6362):728–730. doi: 10.1038/355728a0. [DOI] [PubMed] [Google Scholar]
  15. Fultz P. N., McClure H. M., Swenson R. B., McGrath C. R., Brodie A., Getchell J. P., Jensen F. C., Anderson D. C., Broderson J. R., Francis D. P. Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome. J Virol. 1986 Apr;58(1):116–124. doi: 10.1128/jvi.58.1.116-124.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fung M. S., Sun C. R., Gordon W. L., Liou R. S., Chang T. W., Sun W. N., Daar E. S., Ho D. D. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol. 1992 Feb;66(2):848–856. doi: 10.1128/jvi.66.2.848-856.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Giavedoni L. D., Planelles V., Haigwood N. L., Ahmad S., Kluge J. D., Marthas M. L., Gardner M. B., Luciw P. A., Yilma T. D. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol. 1993 Jan;67(1):577–583. doi: 10.1128/jvi.67.1.577-583.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Girard M., Kieny M. P., Pinter A., Barre-Sinoussi F., Nara P., Kolbe H., Kusumi K., Chaput A., Reinhart T., Muchmore E. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):542–546. doi: 10.1073/pnas.88.2.542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Groenink M., Fouchier R. A., Broersen S., Baker C. H., Koot M., van't Wout A. B., Huisman H. G., Miedema F., Tersmette M., Schuitemaker H. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science. 1993 Jun 4;260(5113):1513–1516. doi: 10.1126/science.8502996. [DOI] [PubMed] [Google Scholar]
  20. Haigwood N. L., Shuster J. R., Moore G. K., Lee H., Skiles P. V., Higgins K. W., Barr P. J., George-Nascimento C., Steimer K. S. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res Hum Retroviruses. 1990 Jul;6(7):855–869. doi: 10.1089/aid.1990.6.855. [DOI] [PubMed] [Google Scholar]
  21. Hirsch V., Riedel N., Mullins J. I. The genome organization of STLV-3 is similar to that of the AIDS virus except for a truncated transmembrane protein. Cell. 1987 May 8;49(3):307–319. doi: 10.1016/0092-8674(87)90283-2. [DOI] [PubMed] [Google Scholar]
  22. Ho D. D., Fung M. S., Cao Y. Z., Li X. L., Sun C., Chang T. W., Sun N. C. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8949–8952. doi: 10.1073/pnas.88.20.8949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hu S. L., Abrams K., Barber G. N., Moran P., Zarling J. M., Langlois A. J., Kuller L., Morton W. R., Benveniste R. E. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science. 1992 Jan 24;255(5043):456–459. doi: 10.1126/science.1531159. [DOI] [PubMed] [Google Scholar]
  24. Hu S. L., Travis B. M., Stallard V., Abrams K., Misher L., Moran P., Zarling J. M., Langlois A. J., Kuller L., Morton W. R. Immune responses to SIVmne envelope glycoproteins protect macaques from homologous SIV infection. AIDS Res Hum Retroviruses. 1992 Aug;8(8):1489–1494. doi: 10.1089/aid.1992.8.1489. [DOI] [PubMed] [Google Scholar]
  25. Israel Z. R., Edmonson P. F., Maul D. H., O'Neil S. P., Mossman S. P., Thiriart C., Fabry L., Van Opstal O., Bruck C., Bex F. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol. 1994 Mar;68(3):1843–1853. doi: 10.1128/jvi.68.3.1843-1853.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Javaherian K., Langlois A. J., Schmidt S., Kaufmann M., Cates N., Langedijk J. P., Meloen R. H., Desrosiers R. C., Burns D. P., Bolognesi D. P. The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1418–1422. doi: 10.1073/pnas.89.4.1418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Johnson P. R., Montefiori D. C., Goldstein S., Hamm T. E., Zhou J., Kitov S., Haigwood N. L., Misher L., London W. T., Gerin J. L. Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2175–2179. doi: 10.1073/pnas.89.6.2175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kent K. A., Gritz L., Stallard G., Cranage M. P., Collignon C., Thiriart C., Corcoran T., Silvera P., Stott E. J. Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. AIDS. 1991 Jul;5(7):829–836. doi: 10.1097/00002030-199107000-00006. [DOI] [PubMed] [Google Scholar]
  29. Kent K. A., Rud E., Corcoran T., Powell C., Thiriart C., Collignon C., Stott E. J. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Res Hum Retroviruses. 1992 Jun;8(6):1147–1151. doi: 10.1089/aid.1992.8.1147. [DOI] [PubMed] [Google Scholar]
  30. Koito A., Harrowe G., Levy J. A., Cheng-Mayer C. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol. 1994 Apr;68(4):2253–2259. doi: 10.1128/jvi.68.4.2253-2259.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Kornfeld H., Riedel N., Viglianti G. A., Hirsch V., Mullins J. I. Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses. Nature. 1987 Apr 9;326(6113):610–613. doi: 10.1038/326610a0. [DOI] [PubMed] [Google Scholar]
  32. Le Grand R., Vaslin B., Vogt G., Roques P., Humbert M., Dormont D. AIDS vaccine developments. Nature. 1992 Feb 20;355(6362):684–684. doi: 10.1038/355684a0. [DOI] [PubMed] [Google Scholar]
  33. Letvin N. L., Daniel M. D., Sehgal P. K., Desrosiers R. C., Hunt R. D., Waldron L. M., MacKey J. J., Schmidt D. K., Chalifoux L. V., King N. W. Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science. 1985 Oct 4;230(4721):71–73. doi: 10.1126/science.2412295. [DOI] [PubMed] [Google Scholar]
  34. Lewis M. G., Elkins W. R., McCutchan F. E., Benveniste R. E., Lai C. Y., Montefiori D. C., Burke D. S., Eddy G. A., Shafferman A. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine. 1993 Oct;11(13):1347–1355. doi: 10.1016/0264-410x(93)90106-8. [DOI] [PubMed] [Google Scholar]
  35. Li J., Lord C. I., Haseltine W., Letvin N. L., Sodroski J. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr. 1992;5(7):639–646. [PubMed] [Google Scholar]
  36. Mascola J. R., Mathieson B. J., Zack P. M., Walker M. C., Halstead S. B., Burke D. S. Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res Hum Retroviruses. 1993 Dec;9(12):1175–1184. doi: 10.1089/aid.1993.9.1175. [DOI] [PubMed] [Google Scholar]
  37. Masuda T., Matsushita S., Kuroda M. J., Kannagi M., Takatsuki K., Harada S. Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region. J Immunol. 1990 Nov 15;145(10):3240–3246. [PubMed] [Google Scholar]
  38. McBride B. W., Corthals G., Rud E., Kent K., Webster S., Cook N., Cranage M. P. Comparison of serum antibody reactivities to a conformational and to linear antigenic sites in the external envelope glycoprotein of simian immunodeficiency virus (SIVmac) induced by infection and vaccination. J Gen Virol. 1993 Jun;74(Pt 6):1033–1041. doi: 10.1099/0022-1317-74-6-1033. [DOI] [PubMed] [Google Scholar]
  39. McKeating J. A., Shotton C., Cordell J., Graham S., Balfe P., Sullivan N., Charles M., Page M., Bolmstedt A., Olofsson S. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J Virol. 1993 Aug;67(8):4932–4944. doi: 10.1128/jvi.67.8.4932-4944.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Michel M. L., Mancini M., Riviere Y., Dormont D., Tiollais P. T- and B-lymphocyte responses to human immunodeficiency virus (HIV) type 1 in macaques immunized with hybrid HIV/hepatitis B surface antigen particles. J Virol. 1990 May;64(5):2452–2455. doi: 10.1128/jvi.64.5.2452-2455.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Michel M. L., Mancini M., Sobczak E., Favier V., Guetard D., Bahraoui E. M., Tiollais P. Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV--hepatitis B surface antigen particles. Proc Natl Acad Sci U S A. 1988 Nov;85(21):7957–7961. doi: 10.1073/pnas.85.21.7957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Michel M. L., Pontisso P., Sobczak E., Malpièce Y., Streeck R. E., Tiollais P. Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin. Proc Natl Acad Sci U S A. 1984 Dec;81(24):7708–7712. doi: 10.1073/pnas.81.24.7708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Miller M. A., Murphey-Corb M., Montelaro R. C. Identification of broadly reactive continuous antigenic determinants of simian immunodeficiency virus glycoproteins. AIDS Res Hum Retroviruses. 1992 Jun;8(6):1153–1164. doi: 10.1089/aid.1992.8.1153. [DOI] [PubMed] [Google Scholar]
  44. Moore J. P., Sattentau Q. J., Yoshiyama H., Thali M., Charles M., Sullivan N., Poon S. W., Fung M. S., Traincard F., Pinkus M. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. J Virol. 1993 Oct;67(10):6136–6151. doi: 10.1128/jvi.67.10.6136-6151.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Murphey-Corb M., Martin L. N., Davison-Fairburn B., Montelaro R. C., Miller M., West M., Ohkawa S., Baskin G. B., Zhang J. Y., Putney S. D. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science. 1989 Dec 8;246(4935):1293–1297. doi: 10.1126/science.2555923. [DOI] [PubMed] [Google Scholar]
  46. Nara P. L., Smit L., Dunlop N., Hatch W., Merges M., Waters D., Kelliher J., Gallo R. C., Fischinger P. J., Goudsmit J. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol. 1990 Aug;64(8):3779–3791. doi: 10.1128/jvi.64.8.3779-3791.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Osterhaus A., de Vries P., Heeney J. AIDS vaccine developments. Nature. 1992 Feb 20;355(6362):684–685. doi: 10.1038/355684b0. [DOI] [PubMed] [Google Scholar]
  48. Peterson D. L., Paul D. A., Lam J., Tribby I. I., Achord D. T. Antigenic structure of hepatitis B surface antigen: identification of the "d" subtype determinant by chemical modification and use of monoclonal antibodies. J Immunol. 1984 Feb;132(2):920–927. [PubMed] [Google Scholar]
  49. Putkonen P., Thorstensson R., Ghavamzadeh L., Albert J., Hild K., Biberfeld G., Norrby E. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature. 1991 Aug 1;352(6334):436–438. doi: 10.1038/352436a0. [DOI] [PubMed] [Google Scholar]
  50. Riviere Y., Tanneau-Salvadori F., Regnault A., Lopez O., Sansonetti P., Guy B., Kieny M. P., Fournel J. J., Montagnier L. Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins. J Virol. 1989 May;63(5):2270–2277. doi: 10.1128/jvi.63.5.2270-2277.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Salter R. D., Howell D. N., Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics. 1985;21(3):235–246. doi: 10.1007/BF00375376. [DOI] [PubMed] [Google Scholar]
  52. Samuelsson A., Björling E., Putkonen P., Utter G., Chiodi F., Norrby E. Identification of four antibody-binding sites in the envelope proteins of simian immunodeficiency virus, SIVsm. AIDS. 1993 Feb;7(2):159–165. doi: 10.1097/00002030-199302000-00002. [DOI] [PubMed] [Google Scholar]
  53. Schlienger K., Mancini M., Rivière Y., Dormont D., Tiollais P., Michel M. L. Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates. J Virol. 1992 Apr;66(4):2570–2576. doi: 10.1128/jvi.66.4.2570-2576.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Schwartz O., Henin Y., Marechal V., Montagnier L. A rapid and simple colorimetric test for the study of anti-HIV agents. AIDS Res Hum Retroviruses. 1988 Dec;4(6):441–448. doi: 10.1089/aid.1988.4.441. [DOI] [PubMed] [Google Scholar]
  55. Shafferman A., Jahrling P. B., Benveniste R. E., Lewis M. G., Phipps T. J., Eden-McCutchan F., Sadoff J., Eddy G. A., Burke D. S. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7126–7130. doi: 10.1073/pnas.88.16.7126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Shioda T., Levy J. A., Cheng-Mayer C. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature. 1991 Jan 10;349(6305):167–169. doi: 10.1038/349167a0. [DOI] [PubMed] [Google Scholar]
  57. Stott E. J. Anti-cell antibody in macaques. Nature. 1991 Oct 3;353(6343):393–393. doi: 10.1038/353393a0. [DOI] [PubMed] [Google Scholar]
  58. Stott E. J., Chan W. L., Mills K. H., Page M., Taffs F., Cranage M., Greenaway P., Kitchin P. Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet. 1990 Dec 22;336(8730):1538–1541. doi: 10.1016/0140-6736(90)93310-l. [DOI] [PubMed] [Google Scholar]
  59. Sullivan N., Thali M., Furman C., Ho D. D., Sodroski J. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J Virol. 1993 Jun;67(6):3674–3679. doi: 10.1128/jvi.67.6.3674-3679.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Talbot P. J., Salmi A. A., Knobler R. L., Buchmeier M. J. Topographical mapping of epitopes on the glycoproteins of murine hepatitis virus-4 (strain JHM): correlation with biological activities. Virology. 1984 Jan 30;132(2):250–260. doi: 10.1016/0042-6822(84)90032-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Tremblay M., Wainberg M. A. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J Infect Dis. 1990 Sep;162(3):735–737. doi: 10.1093/infdis/162.3.735. [DOI] [PubMed] [Google Scholar]
  62. Westervelt P., Trowbridge D. B., Epstein L. G., Blumberg B. M., Li Y., Hahn B. H., Shaw G. M., Price R. W., Ratner L. Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo. J Virol. 1992 Apr;66(4):2577–2582. doi: 10.1128/jvi.66.4.2577-2582.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Yoshiyama H., Mo H., Moore J. P., Ho D. D. Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop. J Virol. 1994 Feb;68(2):974–978. doi: 10.1128/jvi.68.2.974-978.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES